Expression of NY-ESO-1 and LAGE-1 cancer-testis antigens in hepatocellular carcinoma.
- Author:
Wen-min ZHANG
1
;
Gang XIAO
;
Meng ZHANG
;
Ai-lin GUO
;
Yu DONG
;
Jian-ming WEN
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antigens, Neoplasm; biosynthesis; genetics; Antigens, Surface; biosynthesis; genetics; Carcinoma, Hepatocellular; metabolism; pathology; Female; Gene Expression Regulation, Neoplastic; Humans; Liver; metabolism; pathology; Liver Neoplasms; metabolism; pathology; Male; Membrane Proteins; biosynthesis; genetics; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; RNA, Messenger; biosynthesis; genetics
- From: Chinese Journal of Pathology 2005;34(4):202-205
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the role of NY-ESO-1 and LAGE-1 cancer-testis antigens as targets for immunotherapy and the relationship between corresponding gene expression and biologic behavior of hepatocellular carcinoma (HCC).
METHODSThe expression of NY-ESO-1 and LAGE-1 was studied in frozen tumor tissues from 30 cases of HCC by reverse transcriptase-polymerase chain reaction and immunohistochemistry. NY-ESO-1 expression and its distribution were further studied by immunohistochemistry in a tissue array contained 191 cases of HCC.
RESULTSNY-ESO-1 and LAGE-1 mRNAs were expressed in 33.3% (10/30) and 16.7% (5/30) of HCC respectively. Either NY-ESO-1 or LAGE-1 was expressed in 36.7% (11/30) cases. NY-ESO-1 was expressed mainly in the cytoplasm of tumor cells. It was positive in 13.8% (24/174) cases of HCC. There was an increased expression of NY-ESO-1 from 6.8%, 3/44 in small HCC, 16.2%, 21/130 in advanced HCC and 23.1%, 12/52 in metastatic HCC. The expression in the non-metastatic group was 9.8% (12/122). The differences between the metastatic group and non-metastatic group (< 0.05) and between normal liver tissue and HCC (< 0.01) were statistically significant. There was no relationship between NY-ESO-1 expression and tumor size. NY-ESO-1 and LAGE-1 were not detected in adjacent normal liver tissue.
CONCLUSIONSNY-ESO-1 and LAGE-1 are expressed in a high percentage of HCC, especially in cases with metastasis. It is thus possible that NY-ESO-1/LAGE-1 can serve as targets for antigen-specific immunotherapy in HCC and NY-ESO-1 peptide vaccination may be of use for patients with advanced HCC.
